Key facts
- LangAware’s last known valuation is $12.1M (Oct 2023).
- It has raised $4.6M; the latest was Later Stage VC ($320K) in Mar 2025.
- Notable investors include Endeavor Greece, Eleven Ventures, Cleverage Venture Capital, Georgios Georgios, Metavallon VC — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for LangAware
- ·The full record, as it builds
Funding rounds
No funding rounds for LangAware are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LangAware
Developer of diagnosis technology designed to be used for the early detection of various neurodegenerative diseases. The company's technology uses artificial intelligence and machine learning to predict neurodegenerative diseases by detecting and monitoring digital biomarkers based on language and speech, enabling physicians and patients to have an early cognitive assessment to prevent Alzheimer's and related dementias.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2019
- Employees
- 11
- Website
- langaware.com/
- Ownership
- Privately Held (backing)
LangAware doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LangAware shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LangAware in its N-PORT filings yet. We sweep new filings monthly.